The power of the partnership
GORE® technology and the power of the AGC Biologics CDMO network combine to offer a new way to advance products into the clinic, offering the benefit of continuous bioprocessing, without the risk.
Improve your downstream purification through a unique blend of GORE's protein capture devices and AGC Biologics' innovative global scientific network and single-use manufacturing systems.
GORE's technology for increasing the productivity of the Protein A step seamlessly plugs into AGC's purification steps for your drug substance, giving you innovative purification technology alongside a global manufacturing network offering 30 years of scientific and regulatory expertise.
Using GORE alongside AGC Biologics' CDMO services, you get consistent scale-up performance rivaling resin-based systems without the complexity and expense of new equipment or re-engineering.
Learn about our mAb offerings
Study: Protein A Membrane vs. Resin Columns
A comparison of this new protein A capture technology with traditional resin-based approaches.
Access Research
Research: Membrane Technology in Protein A Affinity Capture
Overcoming barriers to adopting membrane technology by demonstrating protein A affinity capture step
Technical Note: Hydrodynamic Shear & Turbulent Flow
Hydrodynamic shear and turbulent flow considerations for high productivity membranes
It's simple. Improve your downstream purification productivity of the Protein A step using GORE's technology, and leverage world-class development, analytical and quality control services from AGC Biologics.
The power of Protein A: The new age of personalized medicine often means smaller batches with higher potency and lower doses. Traditional protein A resin tends to be oversized and underutilized leading to a larger manufacturing footprint, waste, and a more complex process incurring higher costs for clinical bioprocessing and GMP manufacturing. GORE technology, reduces complexity and risk and has been demonstrated to boost productivity 6-10x over resin, to simplify one of the most expensive and critical steps in your clinical journey.
The promise of single-use manufacturing technology: AGC Biologics can offer increased flexibility and lower clinical and commercial manufacturing costs for customers via a single-use technology platform. This is backed by a strong supply chain and decades of regulatory expertise.
With both, you can achieve your continuous bioprocessing productivity goals, at the best manufacturing yields possible, while staying within a well-characterized and validated batch process.
Setting a new standard in downstream processing
Download this article on how AGC Biologics and GORE are working together to boost productivity in antibody-based therapies.
View ArticleRead the full press release
AGC and Gore Collaborate on Antibody Protein A-based Purification & CDMO Services
.png?width=2594&height=1296&name=GORE%20Social%20Graphic%201%20(1).png)
About Gore
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion. For more information, visit gore.com.
